Wagner, Sabine and Peters, Ove and Fels, Christin and Janssen, Gisela and Liebeskind, Anne-Kathrin and Sauerbrey, Axel and Suttorp, Meinolf and Hau, Peter and Wolff, Johannes E. A. (2008) Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors. JOURNAL OF NEURO-ONCOLOGY, 86 (2). pp. 175-181. ISSN 0167-594X,
Full text not available from this repository. (Request a copy)Abstract
Background: The combination of topoisomerase I and II chemotherapeutic agents has shown promising preclinical synergistic effects in the treatment of high-grade malignant brain tumors such as high-grade gliomas and choroid plexus carcinomas. To confirm the effectiveness of this treatment combination and determine its possible toxicity, we conducted a retrospective review of the charts of children who received the therapy. Methods: Patients with relapsed malignant brain tumors who were given an individualized treatment of pegylated (PEG)-liposomal doxorubicin and topotecan were included in our study. PEG-liposomal doxorubicin was given intravenously at a dosage of 30-40 mg/m(2) stop over 4 h once every 4 weeks. Additionally, an intravenous formulation of topotecan was given orally twice daily and was increased on an individual basis from a starting dosage of 0.3 mg/m(2) stop per application to a total daily dosage of 0.6 mg/m(2) stop. Results: Eight patients were included. The main toxicity (NCI-CTC) after three cycles of the combination therapy was grade IV hematotoxicity (n = 3); grade III hematotoxicity (n = 2), grade III stomatitis (n = 1), grade III infection (n = 2), grade III diarrhea (n = 1); and grade II dermatitis (n = 1). In four patients, stable disease was achieved for 9, 23, more than 24, and more than 48 weeks, respectively. Conclusion: The schedule of PEG-liposomal doxorubicin with 30-40 mg/m(2) stop every 4 weeks in combination with oral topotecan resulted in tumor response, but the toxicity was high. An individualized increasing dose of PEG-liposomal doxorubicin 10-20 mg/m(2) stop every two weeks is now recommended.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | METASTATIC BREAST-CARCINOMA; PEDIATRIC-ONCOLOGY-GROUP; SOLID TUMORS; PHASE-II; THERAPEUTIC EFFICACY; TOPOISOMERASE-II; GLIOMA; RECURRENT; ADRIAMYCIN; TOXICITY; liposomal doxorubicin; oral topotecan; children; brain tumors |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Kinder- und Jugendmedizin |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 18 Nov 2020 07:41 |
| Last Modified: | 18 Nov 2020 07:41 |
| URI: | https://pred.uni-regensburg.de/id/eprint/31690 |
Actions (login required)
 |
View Item |
